ClinicalTrials.gg
CompletedNCT01086410Updated Jan 18, 2017Results posted

Safety Study of the Effects of Inhaled Fluticasone Furoate/GW642444 on the Hypothalamic-Pituitary-Adrenal (HPA) Axis

A Phase 3 interventional study of Placebo Inhalation Powder and Fluticasone Furoate/GW642444 Inhalation Powder in Asthma, sponsored by GlaxoSmithKline. Completed at 17 sites in 3 countries. Open to participants aged 12 Years to 65 Years. Per ClinicalTrials.gov, last updated 2017-01-18.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
185
Allocation
Randomized
Ages
12 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 40 studies testing fluticasone furoate in Asthma — none open to participants now, 3 under way, 2 of them phase 3. fluticasone furoate · Asthma.

Enrollment
19th of 40
185 · median 102
Started
2010
with 6 others
Phase 3
14 of 40
none open now
Registered
11th of 40
by date
Lead sponsor
36 of 40
GlaxoSmithKline

Among the 40 studies testing fluticasone furoate in Asthma, this one is the 19th largest by enrollment, is one of 7 that started in 2010, is one of 14 in phase 3, and was the 11th registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

None of the 40 studies testing fluticasone furoate in Asthma is open now. The open studies under Asthma, anywhere →

About fluticasone furoate

fluticasone furoate: first FDA approval 2007 (FLONASE SENSIMIST ALLERGY RELIEF), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 12 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 40 studies testing fluticasone furoate in Asthma as a file.
02

Study summary

The purpose of this study is to assess the effect of six weeks' treatment with two once-daily strengths of Fluticasone Furoate/GW642444 Inhalation Powder on the HPA axis system

03

Conditions studied

  • Asthma

Browse trials for

Keywords

  • HPA axis
04

Who can participate

Ages eligible
12 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Outpatient with ability to comply with study requirements and complete two 24-hour clinic visits
  • Clinical diagnosis of asthma for greater than/equal to 12 weeks
  • Reversibility of at least twelve percent and two hundred milliliters
  • FEV1 greater than or equal to fifty percent of predicted

Exclusion criteria

Exclusion Criteria:

  • History of life threatening asthma
  • Respiratory infection or oral candidiasis
  • Asthma exacerbation
  • Uncontrolled disease or clinical abnormality
  • Allergies to study drugs, study drugs' , medications related to study drugs
  • Taking another medication or prohibited medication
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
185 participants (actual)

Study arms

  • Active comparator
    FF/444 Dose B

    Fluticasone furoate/GW642444 Dose B inhalation powder once daily for 6 weeks' treatment + 1 oral placebo capsule each day on the last 7 days of the study

    Drug: Fluticasone Furoate/GW642444 Inhalation Powder · Drug: Placebo Oral Capsule

  • Active comparator
    FF/444 Dose A

    Fluticasone furoate/GW642444 Dose A inhalation powder once daily for 6 weeks' treatment + 1 oral placebo capsule each day on the last 7 days of the study

    Drug: Fluticasone Furoate/GW642444 Inhalation Powder · Drug: Placebo Oral Capsule

  • Placebo comparator
    Placebo

    Placebo inhalation powder once daily for 6 weeks' treatment + 1 oral placebo capsule each day on the last 7 days of the study

    Drug: Placebo Inhalation Powder · Drug: Placebo Oral Capsule

  • Active comparator
    Prednisolone

    Placebo inhalation powder once daily for 6 weeks' treatment + 1 oral prednisolone 10mg capsule each day on the last 7 days of the study

    Drug: Placebo Inhalation Powder · Drug: Prednisolone Oral Capsule

Interventions

  • DrugPlacebo Inhalation Powder

    Placebo Inhalation powder inhaled once daily for 6 weeks' treatment

  • DrugFluticasone Furoate/GW642444 Inhalation Powder

    Drug pages: Fluticasone furoate · Vilanterol

    Dose B inhaled once daily for 6 weeks' treatment

  • DrugFluticasone Furoate/GW642444 Inhalation Powder

    Drug pages: Fluticasone furoate · Vilanterol

    Dose A inhaled once daily for 6 weeks' treatment

  • DrugPlacebo Oral Capsule

    One placebo capsule taken each day on the last 7 days of the study

  • Prednisolone 10mg oral capsule taken each day on the last 7 days of the study

06

What researchers measure

Primary outcomes

  1. Ratio From Baseline of the Serum Cortisol Weighted Mean (0-24 Hours) on Day -1/1 (Baseline) and Day 42

    Serum cortisol weighted mean was determined for each participant over the time period 0-12 hours on Day -1/1 (Baseline) and Day 42. Serum cortisol weighted mean was derived by dividing the area under the concentration-time curve (AUC; defined as thearea under the concentration-time curve from time zero up to 24 hours) by the sample collection time interval. The sample collection time interval is defined as the difference between the time of the last cortisol sample and the time of the first cortisol sample. Samples were collected at the following time points: 0 (first blood draw/pre-dose); 2, 4, 9, 12, 14, 16, 20, 22, and 24 hours (relative to the "0" time point). Because values are on a logged scale, the ratio of the endpoint to Baseline is presented, as it is a measure of the difference from Baseline.

    Time frame: Day -1/1 (Baseline) and Day 42

Secondary outcomes

  1. Ratio From Baseline of the Serum Cortisol Area Under the Concentration-time Curve (AUC) (0-24 Hour) on Day -1/1 (Baseline) and Day 42

    Area under the plasma drug concentration-time (AUC\[0-24 hour\]) curve from time zero (pre-dose) to the last time of quantifiable serum cortisol concentration at 24 hours post-dose on Day -1/1 (Baseline) and Day 42 was measured. AUC reflects the actual body exposure to drug over a specified period of time after administration of a dose. Samples were collected at the following times: 0 (immediately pre-dose inhaled study drug); post-dose at 5 minutes (min), 15 min, 30 min, and 1 hour (hr), 2 hr, 4 hr, 9 hr, 12 hr, 16 hr, 20 hr, and 24 hr. Because values are on a logged scale, the ratio of the endpoint to Baseline is presented, as it is a measure of the difference from Baseline.

    Time frame: Day -1/1 (Baseline) and Day 42

  2. Ratio From Baseline of Serum Cortisol Trough (0-24 Hours) at Day -1/1 (Baseline) and Day 42

    Serum cortisol trough is defined as the minimum value of serum cortisol measured over the 24-hour period. Samples were collected at the following times: 0 (immediately pre-dose inhaled study drug); post-dose at 5 minutes (min), 15 min, 30 min, and 1 hour (hr), 2 hr, 4 hr, 9 hr, 12 hr, 16 hr, 20 hr, and 24 hr. Because values are on a logged scale, the ratio of the endpoint to Baseline is presented, as it is a measure of the difference from Baseline.

    Time frame: Day -1/1 (Baseline) and Day 42

  3. Ratio From Baseline of 0-24 Hour Urinary Free Cortisol Excretion on Day -1/1 (Baseline) and Day 42

    A 24-hour urine sample was collected for the measurement of 24-hour urinary cortisol excretion at Day -1/1 (Baseline) and Day 42. Only those participants available at the specified time points were analyzed. Because values are on a logged scale, the ratio of the endpoint to Baseline is presented, as it is a measure of the difference from Baseline.

    Time frame: Day -1/1 (Baseline) and Day 42

  4. Plasma FF and VI Pharmacokinetic (PK) Concentration

    Plasma FF and VI Pharmacokinetic (PK) Concentration were estimates at the following time points:0 (immediately pre-dose inhaled study drug), and post-dose at 5 min, 15 min, 30 min, and 1 hr, 2 hr, 4 hr, 9 hr, 12 hr, 16 hr, 20 hr, 24 hr on Day 42. Only those participants available at the specified time points were analyzed (represented by n=X, X, X, X in the category titles). Different participants may have been analyzed at different time points, so the overall number of participants analyzed reflects everyone in the Pharmacokinetic Population.

    Time frame: Day 42

  5. AUC(0-t) and AUC(0-24) for FF on Day 42

    Area under the plasma drug concentration-time (AUC\[0-t\]) curve from time zero (pre-dose) to the last time of quantifiable FF concentration and AUC(0-24) is the concentration time curve from zero (pre-dose) to 24 hours of quantifiable FF concentration on Day 42 was measured. AUC reflects the actual body exposure to drug over a specified period of time after administration of a dose. Samples were collected at the following times: 0 (immediately pre-dose inhaled study drug); post-dose at 5 minutes (min), 15 min, 30 min, and 1 hour (hr), 2 hr, 4 hr, 9 hr, 12 hr, 16 hr, 20 hr, and 24 hr post-dose on Day 42.

    Time frame: Day 42

  6. Cmax for FF on Day 42

    Cmax is defined as the maximum observed concentration on Day 42. Samples were collected at the following times: 0 (immediately pre-dose inhaled study drug); post-dose at 5 minutes (min), 15 min, 30 min, and 1 hour (hr), 2 hr, 4 hr, 9 hr, 12 hr, 16 hr, 20 hr, and 24 hr post-dose on Day 42.

    Time frame: Day 42

  7. Tmax and Tlast of FF at Day 42

    tmax is defined as the time to reach the observed maximum concentration, and tlast is defined as the time of the last observed quantifiable concentration on Day 42. Samples were collected at the following times: 0 (immediately pre-dose inhaled study drug); post-dose at 5 minutes (min), 15 min, 30 min, and 1hour (hr), 2 hr, 4 hr, 9 hr, 12 hr, 16 hr, 20 hr, and 24 hr post-dose on Day 42.

    Time frame: Day 42

  8. AUC(0-t) for VI on Day 42

    Area under the concentration-time (AUC\[0-t\]) curve from time zero (pre-dose) to the last time of quantifiable VI concentration on Day 42 was measured. Samples were collected at the following times: 0 (immediately pre-dose inhaled study drug); post-dose at 5 minutes (min), 15 min, 30 min, and 1 hour (hr), 2 hr, 4 hr, 9 hr, 12 hr, 16 hr, 20 hr, and 24 hr post-dose on Day 42.

    Time frame: Day 42

  9. Cmax for VI on Day 42

    Cmax is defined as the maximum observed concentration on Day 42. Samples were collected at the following times: 0 (immediately pre-dose inhaled study drug); post-dose at 5 minutes (min), 15 min, 30 min, and 1 hour (hr), 2 hr, 4 hr, 9 hr, 12 hr, 16 hr, 20 hr, and 24 hr post-dose on Day 42.

    Time frame: Day 42

  10. Tmax and Tlast of VI at Day 42

    tmax is defined as the time to reach the observed maximum concentration, and tlast is defined as the time of the last observed quantifiable VI concentration on Day 42. Samples were collected at the following times: 0 (immediately pre-dose inhaled study drug); post-dose at 5 minutes (min), 15 min, 30 min, and 1hour (hr), 2 hr, 4 hr, 9 hr, 12 hr, 16 hr, 20 hr, and 24 hr post-dose on Day 42.

    Time frame: Day 42

  11. Number of Participants With Any Adverse Event (AE) or Any Serious Adverse Event (SAE) During the Treatment Period

    An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. A serious adverse event (SAE) is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect. Medical or scientific judgment should be exercised in deciding whether reporting is appropriate in other situations. Refer to the General Adverse AE/SAE module for a complete list of AEs and SAEs.

    Time frame: From the start of study medication until Day 42 (Visit 5)/Early Withdrawal

  12. Change From Baseline in Basophil, Eosinophil, Lymphocyte, Monocyte, and Segmented Neutrophil Values at Day 42/Early Withdrawal (EW)

    Blood samples were collected for the measurement of basophils, eosinophils, lymphocytes, monocytes, and segmented neutrophils at Baseline and Day 42/EW. For all laboratory assessments, Baseline is the most recent recorded value at Screening or prior to Day -1/1. Change from Baseline was calculated as the Day 42/EW value minus the Baseline value.

    Time frame: Baseline and Day 42/Early Withdrawal (EW)

  13. Change From Baseline in Eosinophil, Total Neutrophil, Platelet, and White Blood Cell (WBC) Count Values at Day 42/EW

    Blood samples were collected for the measurement of eosinophils, total neutrophils, platelets, and WBC count at Baseline and Day 42/EW. For all laboratory assessments, Baseline is the most recent recorded value at Screening or prior to Day -1/1. Change from Baseline was calculated as the Day 42/EW value minus the Baseline value.

    Time frame: Baseline and Day 42/EW

  14. Change From Baseline in Hemoglobin Values at Day 42/EW

    Blood samples were collected for the measurement of hemoglobin at Baseline and Day 42/EW. For all laboratory assessments, Baseline is the most recent recorded value at Screening or prior to Day -1/1. Change from Baseline was calculated as the Day 42/EW value minus the Baseline value.

    Time frame: Baseline and Day 42/EW

  15. Change From Baseline in Hematocrit Values at Day 42/EW

    Blood samples were collected for the measurement of hematocrit at Baseline and Day 42/EW. For all laboratory assessments, Baseline is the most recent recorded value at Screening or prior to Day -1/1. Change from Baseline was calculated as the Day 42/EW value minus the Baseline value.

    Time frame: Baseline and Day 42/EW

  16. Change From Baseline in Alanine Amino Transferase (ALT), Alkaline Phosphatase (ALP), Aspartate Amino Transferase (AST), Creatine Kinase (CK), and Gamma Glutamyl Transferase (GGT) Values at Day 42/EW

    Blood samples were collected for the measurement of ALT, ALP, AST, CK, and GGT at Baseline and Day 42/EW. For all laboratory assessments, Baseline is the most recent recorded value at Screening or prior to Day -1/1. Change from Baseline was calculated as the Day 42/EW value minus the Baseline value.

    Time frame: Baseline and Day 42/EW

  17. Change From Baseline in Albumin and Total Protein Values at Day 42/EW

    Blood samples were collected for the measurement of albumin and total protein at Baseline and Day 42/EW. For all laboratory assessments, Baseline is the most recent recorded value at Screening or prior to Day -1/1. Change from Baseline was calculated as the Day 42/EW value minus the Baseline value.

    Time frame: Baseline and Day 42/EW

  18. Change From Baseline in Direct Bilirubin, Indirect Bilirubin, Total Bilirubin, and Creatinine Values at Day 42/EW

    Blood samples were collected for the measurement of direct bilirubin, indirect bilirubin, total bilirubin, and creatinine at Baseline and Day 42/EW. For all laboratory assessments, Baseline is the most recent recorded value at Screening or prior to Day -1/1. Change from Baseline was calculated as the Day 42/EW value minus the Baseline value.

    Time frame: Baseline and Day 42/EW

  19. Change From Baseline in Chloride, Carbon Dioxide (CO2) Content/Bicarbonate, Glucose, Potassium, Sodium, and Urea/Blood Urea Nitrogen (BUN) Values at Day 42/EW

    Blood samples were collected for the measurement of chloride, carbon dioxide (CO2) content/bicarbonate, glucose, potassium, sodium, and urea/blood urea nitrogen (BUN) at Baseline and Day 42/EW. For all laboratory assessments, Baseline is the most recent recorded value at Screening or prior to Day -1/1. Change from Baseline was calculated as the Day 42/EW value minus the Baseline value.

    Time frame: Baseline and Day 42/EW

  20. Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at Days 14, 28, 42, and Maximum Post-Baseline

    SBP and DBP were measured at Baseline and at Days 14, 28, 42, and EW. Change from Baseline was calculated as the Day 42/EW value minus the Baseline value. Scheduled, unscheduled, and early withdrawal visits were used for the maximum post-Baseline assessment.

    Time frame: Days 14, 28, 42, and EW

  21. Change From Baseline in Pulse Rate at Days 14, 28, 42, and Maximum Post-Baseline

    Heart rate was measured at Baseline and at Days 14, 28, 42, and EW. Change from Baseline was calculated as the Day 42/EW value minus the Baseline value. Scheduled, unscheduled, and early withdrawal visits were used for the maximum post-Baseline assessment.

    Time frame: Days 14, 28, 42, and EW

07

Results

Posted Aug 8, 2013

Participant flow

Participants who met all the inclusion criteria entered a 7- to 14-day Run-in Period (screening visit \[Visit 1\]). Participants were provided with albuterol/salbutamol inhalation aerosol for relief of asthma symptoms during the study.

Participant flow — Overall Study
MilestonePlaceboFF/VI 100/25 µg PMFF/VI 200/25 µg PMPrednisolone 10 mg AM
Started58565615
Completed55545513
Not completed3212
Withdrew: Adverse event1002
Withdrew: Lack of efficacy1100
Withdrew: Protocol violation1100
Withdrew: Lost to follow-up0010

Outcome measures

PrimaryRatio From Baseline of the Serum Cortisol Weighted Mean (0-24 Hours) on Day -1/1 (Baseline) and Day 42

Serum cortisol weighted mean was determined for each participant over the time period 0-12 hours on Day -1/1 (Baseline) and Day 42. Serum cortisol weighted mean was derived by dividing the area under the concentration-time curve (AUC; defined as thearea under the concentration-time curve from time zero up to 24 hours) by the sample collection time interval. The sample collection time interval is defined as the difference between the time of the last cortisol sample and the time of the first cortisol sample. Samples were collected at the following time points: 0 (first blood draw/pre-dose); 2, 4, 9, 12, 14, 16, 20, 22, and 24 hours (relative to the "0" time point). Because values are on a logged scale, the ratio of the endpoint to Baseline is presented, as it is a measure of the difference from Baseline.

Time frame:
Day -1/1 (Baseline) and Day 42
Reported as:
Geometric mean · ratio from Baseline
Ratio From Baseline of the Serum Cortisol Weighted Mean (0-24 Hours) on Day -1/1 (Baseline) and Day 42
ratio from BaselinePlaceboFF/VI 100/25 µg PMFF/VI 200/25 µg PMPrednisolone 10 mg AM
Ratio From Baseline of the Serum Cortisol Weighted Mean (0-24 Hours) on Day -1/1 (Baseline) and Day 420.99 ± 29.60.99 ± 40.00.96 ± 27.20.32 ± 72.9
Statistical analysis
  • Placebo vs FF/VI 100/25 µg PM · Ratio of least square gometric mean: 0.99 · 95% CI 0.87 to 1.12Analysis was performed using Analysis of Covariance (ANCOVA) with covariates of region, sex, age, treatment, and the log of the Baseline values.
  • Placebo vs FF/VI 200/25 µg PM · Ratio of least square gometric mean: 0.97 · 95% CI 0.86 to 1.10Analysis was performed using ANCOVA with covariates of region, sex, age, treatment, and the log of the Baseline values.
  • Placebo vs Prednisolone 10 mg AM · Ratio of least square gometric mean: 0.34 · 95% CI 0.28 to 0.41Analysis performed using ANCOVA with covariates of region, sex, age, treatment, and the log of the Baseline values.
SecondaryRatio From Baseline of the Serum Cortisol Area Under the Concentration-time Curve (AUC) (0-24 Hour) on Day -1/1 (Baseline) and Day 42

Area under the plasma drug concentration-time (AUC\[0-24 hour\]) curve from time zero (pre-dose) to the last time of quantifiable serum cortisol concentration at 24 hours post-dose on Day -1/1 (Baseline) and Day 42 was measured. AUC reflects the actual body exposure to drug over a specified period of time after administration of a dose. Samples were collected at the following times: 0 (immediately pre-dose inhaled study drug); post-dose at 5 minutes (min), 15 min, 30 min, and 1 hour (hr), 2 hr, 4 hr, 9 hr, 12 hr, 16 hr, 20 hr, and 24 hr. Because values are on a logged scale, the ratio of the endpoint to Baseline is presented, as it is a measure of the difference from Baseline.

Time frame:
Day -1/1 (Baseline) and Day 42
Reported as:
Geometric mean · ratio from Baseline
Ratio From Baseline of the Serum Cortisol Area Under the Concentration-time Curve (AUC) (0-24 Hour) on Day -1/1 (Baseline) and Day 42
ratio from BaselinePlaceboFF/VI 100/25 µg PMFF/VI 200/25 µg PMPrednisolone 10 mg AM
Ratio From Baseline of the Serum Cortisol Area Under the Concentration-time Curve (AUC) (0-24 Hour) on Day -1/1 (Baseline) and Day 420.99 ± 29.60.99 ± 40.10.97 ± 27.20.32 ± 71.9
SecondaryRatio From Baseline of Serum Cortisol Trough (0-24 Hours) at Day -1/1 (Baseline) and Day 42

Serum cortisol trough is defined as the minimum value of serum cortisol measured over the 24-hour period. Samples were collected at the following times: 0 (immediately pre-dose inhaled study drug); post-dose at 5 minutes (min), 15 min, 30 min, and 1 hour (hr), 2 hr, 4 hr, 9 hr, 12 hr, 16 hr, 20 hr, and 24 hr. Because values are on a logged scale, the ratio of the endpoint to Baseline is presented, as it is a measure of the difference from Baseline.

Time frame:
Day -1/1 (Baseline) and Day 42
Reported as:
Geometric mean · ratio from Baseline
Ratio From Baseline of Serum Cortisol Trough (0-24 Hours) at Day -1/1 (Baseline) and Day 42
ratio from BaselinePlaceboFF/VI 100/25 µg PMFF/VI 200/25 µg PMPrednisolone 10 mg AM
Ratio From Baseline of Serum Cortisol Trough (0-24 Hours) at Day -1/1 (Baseline) and Day 421.04 ± 88.20.84 ± 88.70.73 ± 80.70.28 ± 82.3
SecondaryRatio From Baseline of 0-24 Hour Urinary Free Cortisol Excretion on Day -1/1 (Baseline) and Day 42

A 24-hour urine sample was collected for the measurement of 24-hour urinary cortisol excretion at Day -1/1 (Baseline) and Day 42. Only those participants available at the specified time points were analyzed. Because values are on a logged scale, the ratio of the endpoint to Baseline is presented, as it is a measure of the difference from Baseline.

Time frame:
Day -1/1 (Baseline) and Day 42
Reported as:
Geometric mean · ratio from Baseline
Ratio From Baseline of 0-24 Hour Urinary Free Cortisol Excretion on Day -1/1 (Baseline) and Day 42
ratio from BaselinePlaceboFF/VI 100/25 µg PMFF/VI 200/25 µg PMPrednisolone 10 mg AM
Ratio From Baseline of 0-24 Hour Urinary Free Cortisol Excretion on Day -1/1 (Baseline) and Day 420.87 ± 77.9231.03 ± 110.9520.92 ± 96.3120.40 ± 204.433
SecondaryPlasma FF and VI Pharmacokinetic (PK) Concentration

Plasma FF and VI Pharmacokinetic (PK) Concentration were estimates at the following time points:0 (immediately pre-dose inhaled study drug), and post-dose at 5 min, 15 min, 30 min, and 1 hr, 2 hr, 4 hr, 9 hr, 12 hr, 16 hr, 20 hr, 24 hr on Day 42. Only those participants available at the specified time points were analyzed (represented by n=X, X, X, X in the category titles). Different participants may have been analyzed at different time points, so the overall number of participants analyzed reflects everyone in the Pharmacokinetic Population.

Time frame:
Day 42
Reported as:
Mean · picograms per milliliter (pg/mL)
Plasma FF and VI Pharmacokinetic (PK) Concentration
picograms per milliliter (pg/mL)PlaceboFF/VI 100/25 µg PMFF/VI 200/25 µg PMPrednisolone 10 mg AM
FF, 0 hour, n=53, 54—3.57 ± NA10.02 ± NA—
FF, 5 minutes post-dose, n=51, 54—16.65 ± 10.19125.55 ± 14.438—
FF, 15 minutes post-dose, n=50, 54—16.35 ± 10.19828.84 ± 14.441—
FF, 30 minutes post-dose, n=52, 52—17.12 ± 10.58330.68 ± 15.461—
FF, 1 hour post-dose, n=54, 54—16.91 ± 9.63730.07 ± 15.540—
FF, 2 hours post-dose, n=51, 53—15.00 ± 9.27230.20 ± 18.292—
FF, 4 hours post-dose, n=54, 53—9.78 ± NA21.79 ± 11.597—
FF, 9 hours post-dose, n=48, 52—6.20 ± NA15.99 ± 11.667—
FF, 12 hours post-dose, n=51, 55—4.62 ± NA13.37 ± 9.670—
FF, 16 hours post-dose, n=49, 52—2.55 ± NA11.73 ± NA—
FF, 20 hours post-dose, n=51, 51—1.74 ± NA9.28 ± NA—
FF, 24 hours post-dose, n=48, 53—1.55 ± NA7.58 ± NA—
VI, 0 hours, n=52, 54—2.57 ± NA7.95 ± NA—
VI, 5 minutes post-dose, n=50, 54—85.22 ± 70.58290.54 ± 88.794—
VI, 15 minutes post-dose, n=48, 55—62.94 ± 52.02072.53 ± 55.271—
VI, 30 minutes post-dose, n=51, 55—33.38 ± 33.93236.88 ± 33.157—
VI, 1 hour post-dose, n=52, 53—14.63 ± NA20.07 ± NA—
VI, 2 hours post-dose, n=52, 55—7.09 ± NA6.06 ± NA—
VI, 4 hours post-dose, n=52, 54—0.00 ± NA0.45 ± NA—
VI, 9 hours post-dose, n=52, 55—0.00 ± NA0.47 ± NA—
VI, 12 hours post-dose, n=52, 55—0.00 ± NA1.21 ± NA—
VI, 16 hours post-dose, n=51, 52—0.00 ± NA4.76 ± NA—
VI, 20 hours post-dose, n=50, 54—0.00 ± NA0.00 ± NA—
VI, 24 hours post-dose, n=52, 55—1.19 ± NA0.00 ± NA—
SecondaryAUC(0-t) and AUC(0-24) for FF on Day 42

Area under the plasma drug concentration-time (AUC\[0-t\]) curve from time zero (pre-dose) to the last time of quantifiable FF concentration and AUC(0-24) is the concentration time curve from zero (pre-dose) to 24 hours of quantifiable FF concentration on Day 42 was measured. AUC reflects the actual body exposure to drug over a specified period of time after administration of a dose. Samples were collected at the following times: 0 (immediately pre-dose inhaled study drug); post-dose at 5 minutes (min), 15 min, 30 min, and 1 hour (hr), 2 hr, 4 hr, 9 hr, 12 hr, 16 hr, 20 hr, and 24 hr post-dose on Day 42.

Time frame:
Day 42
Reported as:
Geometric mean · picograms*hour per milliliter (pg*hr/mL)
AUC(0-t) and AUC(0-24) for FF on Day 42
picograms*hour per milliliter (pg*hr/mL)PlaceboFF/VI 100/25 µg PMFF/VI 200/25 µg PMPrednisolone 10 mg AM
AUC(0-t), n=54, 55—58.842 (37.706 to 91.825)221.694 (152.697 to 321.868)—
AUC(0-24), n=49, 53—NA (NA to NA)324.015 (267.233 to 392.862)—
SecondaryCmax for FF on Day 42

Cmax is defined as the maximum observed concentration on Day 42. Samples were collected at the following times: 0 (immediately pre-dose inhaled study drug); post-dose at 5 minutes (min), 15 min, 30 min, and 1 hour (hr), 2 hr, 4 hr, 9 hr, 12 hr, 16 hr, 20 hr, and 24 hr post-dose on Day 42.

Time frame:
Day 42
Reported as:
Geometric mean · picograms per milliliter (pg/mL)
Cmax for FF on Day 42
picograms per milliliter (pg/mL)PlaceboFF/VI 100/25 µg PMFF/VI 200/25 µg PMPrednisolone 10 mg AM
Cmax for FF on Day 42—19.388 (16.796 to 22.379)33.017 (28.586 to 38.135)—
SecondaryTmax and Tlast of FF at Day 42

tmax is defined as the time to reach the observed maximum concentration, and tlast is defined as the time of the last observed quantifiable concentration on Day 42. Samples were collected at the following times: 0 (immediately pre-dose inhaled study drug); post-dose at 5 minutes (min), 15 min, 30 min, and 1hour (hr), 2 hr, 4 hr, 9 hr, 12 hr, 16 hr, 20 hr, and 24 hr post-dose on Day 42.

Time frame:
Day 42
Reported as:
Median · hours
Tmax and Tlast of FF at Day 42
hoursPlaceboFF/VI 100/25 µg PMFF/VI 200/25 µg PMPrednisolone 10 mg AM
tmax—0.500 (0.03 to 8.97)0.500 (0.07 to 4.00)—
tlast—9.000 (0.98 to 24.00)20.042 (0.95 to 24.08)—
SecondaryAUC(0-t) for VI on Day 42

Area under the concentration-time (AUC\[0-t\]) curve from time zero (pre-dose) to the last time of quantifiable VI concentration on Day 42 was measured. Samples were collected at the following times: 0 (immediately pre-dose inhaled study drug); post-dose at 5 minutes (min), 15 min, 30 min, and 1 hour (hr), 2 hr, 4 hr, 9 hr, 12 hr, 16 hr, 20 hr, and 24 hr post-dose on Day 42.

Time frame:
Day 42
Reported as:
Mean · picograms*hour per milliliter (pg*hr/mL)
AUC(0-t) for VI on Day 42
picograms*hour per milliliter (pg*hr/mL)PlaceboFF/VI 100/25 µg PMFF/VI 200/25 µg PMPrednisolone 10 mg AM
AUC(0-t) for VI on Day 42—41.177 ± 53.972066.937 ± 142.3461—
SecondaryCmax for VI on Day 42

Cmax is defined as the maximum observed concentration on Day 42. Samples were collected at the following times: 0 (immediately pre-dose inhaled study drug); post-dose at 5 minutes (min), 15 min, 30 min, and 1 hour (hr), 2 hr, 4 hr, 9 hr, 12 hr, 16 hr, 20 hr, and 24 hr post-dose on Day 42.

Time frame:
Day 42
Reported as:
Mean · picograms per milliliter (pg/mL)
Cmax for VI on Day 42
picograms per milliliter (pg/mL)PlaceboFF/VI 100/25 µg PMFF/VI 200/25 µg PMPrednisolone 10 mg AM
Cmax for VI on Day 42—101.227 ± 73.8233118.531 ± 86.8659—
SecondaryTmax and Tlast of VI at Day 42

tmax is defined as the time to reach the observed maximum concentration, and tlast is defined as the time of the last observed quantifiable VI concentration on Day 42. Samples were collected at the following times: 0 (immediately pre-dose inhaled study drug); post-dose at 5 minutes (min), 15 min, 30 min, and 1hour (hr), 2 hr, 4 hr, 9 hr, 12 hr, 16 hr, 20 hr, and 24 hr post-dose on Day 42.

Time frame:
Day 42
Reported as:
Median · hours
Tmax and Tlast of VI at Day 42
hoursPlaceboFF/VI 100/25 µg PMFF/VI 200/25 µg PMPrednisolone 10 mg AM
tmax—0.083 (0.00 to 2.00)0.083 (0.00 to 16.00)—
tlast—0.500 (0.03 to 2.00)0.950 (0.08 to 16.00)—
SecondaryNumber of Participants With Any Adverse Event (AE) or Any Serious Adverse Event (SAE) During the Treatment Period

An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. A serious adverse event (SAE) is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect. Medical or scientific judgment should be exercised in deciding whether reporting is appropriate in other situations. Refer to the General Adverse AE/SAE module for a complete list of AEs and SAEs.

Time frame:
From the start of study medication until Day 42 (Visit 5)/Early Withdrawal
Reported as:
Number · Participants
Number of Participants With Any Adverse Event (AE) or Any Serious Adverse Event (SAE) During the Treatment Period
ParticipantsPlaceboFF/VI 100/25 µg PMFF/VI 200/25 µg PMPrednisolone 10 mg AM
Any AE1623215
Any SAE0000
SecondaryChange From Baseline in Basophil, Eosinophil, Lymphocyte, Monocyte, and Segmented Neutrophil Values at Day 42/Early Withdrawal (EW)

Blood samples were collected for the measurement of basophils, eosinophils, lymphocytes, monocytes, and segmented neutrophils at Baseline and Day 42/EW. For all laboratory assessments, Baseline is the most recent recorded value at Screening or prior to Day -1/1. Change from Baseline was calculated as the Day 42/EW value minus the Baseline value.

Time frame:
Baseline and Day 42/Early Withdrawal (EW)
Reported as:
Mean · Percentage
Change From Baseline in Basophil, Eosinophil, Lymphocyte, Monocyte, and Segmented Neutrophil Values at Day 42/Early Withdrawal (EW)
PercentagePlaceboFF/VI 100/25 µg PMFF/VI 200/25 µg PMPrednisolone 10 mg AM
Basophils, Day 42, n=50, 47, 53, 110.05 ± 0.3540.04 ± 0.356-0.05 ± 0.350-0.08 ± 0.223
Basophils, EW, n=2, 2, 0, 0-0.10 ± 0.1410.10 ± 0.141NA ± NANA ± NA
Eosinophils, Day 42, n=50, 47, 53, 110.57 ± 2.8370.27 ± 2.073-0.99 ± 2.664-1.11 ± 1.488
Eosinophils, EW, n=2, 2, 0, 00.50 ± 0.849-0.55 ± 2.051NA ± NANA ± NA
Lymphocytes, Day 42, n=50, 47, 53, 111.09 ± 6.8361.54 ± 8.853-1.32 ± 7.844-2.48 ± 14.319
Lymphocytes, EW, n=2, 2, 0, 02.90 ± 10.6072.00 ± 2.263NA ± NANA ± NA
Monocytes, Day 42, n=50, 47, 53, 11-0.51 ± 2.074-0.03 ± 3.3330.07 ± 2.581-0.70 ± 1.977
Monocytes, EW, n=2, 2, 0, 0-1.00 ± 0.424-0.70 ± 3.111NA ± NANA ± NA
Segmented Neutrophils, Day 42, n=50, 47, 53, 11-1.16 ± 8.291-1.85 ± 10.2792.30 ± 9.5834.37 ± 15.667
Segmented Neutrophils, EW, n=2, 2, 0, 0-2.30 ± 11.738-0.85 ± 3.465NA ± NANA ± NA
SecondaryChange From Baseline in Eosinophil, Total Neutrophil, Platelet, and White Blood Cell (WBC) Count Values at Day 42/EW

Blood samples were collected for the measurement of eosinophils, total neutrophils, platelets, and WBC count at Baseline and Day 42/EW. For all laboratory assessments, Baseline is the most recent recorded value at Screening or prior to Day -1/1. Change from Baseline was calculated as the Day 42/EW value minus the Baseline value.

Time frame:
Baseline and Day 42/EW
Reported as:
Mean · 10^9 cells per liter (GI/L)
Change From Baseline in Eosinophil, Total Neutrophil, Platelet, and White Blood Cell (WBC) Count Values at Day 42/EW
10^9 cells per liter (GI/L)PlaceboFF/VI 100/25 µg PMFF/VI 200/25 µg PMPrednisolone 10 mg AM
Eosinophils, Day 42, n=50, 47, 53, 110.066 ± 0.22820.044 ± 0.1608-0.022 ± 0.1805-0.036 ± 0.0803
Eosinophils, EW, n=2, 2, 0, 00.015 ± 0.0071-0.060 ± 0.1697NA ± NANA ± NA
Total Neutrophils, Day 42, n=50, 47, 53, 110.017 ± 1.33170.289 ± 1.48730.704 ± 1.24031.435 ± 2.5515
Total Neutrophils, EW, n=2, 2, 0, 0-0.420 ± 1.7253-1.165 ± 0.9970NA ± NANA ± NA
Platelets, Day 42, n=50, 48, 51, 11-11.1 ± 28.72-8.2 ± 31.33-3.9 ± 25.3116.1 ± 16.50
Platelets, EW, n=1, 2, 0, 0-2.0 ± NA-39.5 ± 28.99NA ± NANA ± NA
WBC Day 42, n=50, 47, 53, 110.22 ± 1.5840.71 ± 1.7870.96 ± 1.3671.69 ± 2.418
WBC EW, n=2, 2-0.25 ± 1.344-1.65 ± 0.778NA ± NANA ± NA
SecondaryChange From Baseline in Hemoglobin Values at Day 42/EW

Blood samples were collected for the measurement of hemoglobin at Baseline and Day 42/EW. For all laboratory assessments, Baseline is the most recent recorded value at Screening or prior to Day -1/1. Change from Baseline was calculated as the Day 42/EW value minus the Baseline value.

Time frame:
Baseline and Day 42/EW
Reported as:
Mean · Grams per liter (g/L)
Change From Baseline in Hemoglobin Values at Day 42/EW
Grams per liter (g/L)PlaceboFF/VI 100/25 µg PMFF/VI 200/25 µg PMPrednisolone 10 mg AM
Day 42, n=50, 48, 53, 11-5.8 ± 10.28-6.2 ± 6.23-5.7 ± 6.59-3.5 ± 9.27
EW, n=2, 2, 0, 0-10.5 ± 2.12-3.0 ± 8.49NA ± NANA ± NA
SecondaryChange From Baseline in Hematocrit Values at Day 42/EW

Blood samples were collected for the measurement of hematocrit at Baseline and Day 42/EW. For all laboratory assessments, Baseline is the most recent recorded value at Screening or prior to Day -1/1. Change from Baseline was calculated as the Day 42/EW value minus the Baseline value.

Time frame:
Baseline and Day 42/EW
Reported as:
Mean · Proportion of 1
Change From Baseline in Hematocrit Values at Day 42/EW
Proportion of 1PlaceboFF/VI 100/25 µg PMFF/VI 200/25 µg PMPrednisolone 10 mg AM
Day 42, n=50, 48, 53, 11-0.0123 ± 0.02957-0.0120 ± 0.02125-0.0114 ± 0.02151-0.0072 ± 0.02955
EW, n=2, 2, 0, 0-0.0175 ± 0.00071-0.0050 ± 0.02263NA ± NANA ± NA
SecondaryChange From Baseline in Alanine Amino Transferase (ALT), Alkaline Phosphatase (ALP), Aspartate Amino Transferase (AST), Creatine Kinase (CK), and Gamma Glutamyl Transferase (GGT) Values at Day 42/EW

Blood samples were collected for the measurement of ALT, ALP, AST, CK, and GGT at Baseline and Day 42/EW. For all laboratory assessments, Baseline is the most recent recorded value at Screening or prior to Day -1/1. Change from Baseline was calculated as the Day 42/EW value minus the Baseline value.

Time frame:
Baseline and Day 42/EW
Reported as:
Mean · International units per liter (IU/L)
Change From Baseline in Alanine Amino Transferase (ALT), Alkaline Phosphatase (ALP), Aspartate Amino Transferase (AST), Creatine Kinase (CK), and Gamma Glutamyl Transferase (GGT) Values at Day 42/EW
International units per liter (IU/L)PlaceboFF/VI 100/25 µg PMFF/VI 200/25 µg PMPrednisolone 10 mg AM
ALT, Day 42, n=55, 51, 55, 12-1.3 ± 13.05-2.0 ± 8.49-2.2 ± 10.860.8 ± 3.33
ALT, EW, n=2, 2, 0, 0-5.0 ± 8.490.5 ± 2.12NA ± NANA ± NA
ALP, Day 42, n=55, 51, 55, 12-6.8 ± 11.06-2.1 ± 13.96-2.6 ± 8.33-4.9 ± 9.86
ALP, EW, n=2, 2, 0, 01.5 ± 9.19-1.0 ± 1.41NA ± NANA ± NA
AST, Day 42, n=54, 50, 51, 12-0.1 ± 12.42-1.4 ± 6.82-0.6 ± 6.91-1.8 ± 5.67
AST, EW, n=2, 2, 0, 00.5 ± 0.710.0 ± 1.41NA ± NANA ± NA
CK, Day 42, n=55, 51, 55, 12-42.3 ± 342.74-18.5 ± 289.985.5 ± 67.57-17.3 ± 95.02
CK, EW, n=2, 2, 0, 015.0 ± 21.2133.0 ± 73.54NA ± NANA ± NA
GGT, Day 42, n=55, 51, 55, 12-3.3 ± 10.65-2.5 ± 6.942.2 ± 17.243.1 ± 7.32
GGT, EW, n=2, 2, 0, 0-2.5 ± 6.36-0.5 ± 0.71NA ± NANA ± NA
SecondaryChange From Baseline in Albumin and Total Protein Values at Day 42/EW

Blood samples were collected for the measurement of albumin and total protein at Baseline and Day 42/EW. For all laboratory assessments, Baseline is the most recent recorded value at Screening or prior to Day -1/1. Change from Baseline was calculated as the Day 42/EW value minus the Baseline value.

Time frame:
Baseline and Day 42/EW
Reported as:
Mean · Grams per liter
Change From Baseline in Albumin and Total Protein Values at Day 42/EW
Grams per literPlaceboFF/VI 100/25 µg PMFF/VI 200/25 µg PMPrednisolone 10 mg AM
Albumin, Day 42, n=55, 51, 55, 12-2.7 ± 3.29-1.5 ± 3.02-1.3 ± 3.11-0.3 ± 2.81
Albumin, EW, n=2, 2, 0, 0-1.5 ± 3.540.5 ± 2.12NA ± NANA ± NA
Total Protein, Day 42, n=55, 51, 55, 12-4.1 ± 5.06-1.9 ± 4.39-1.8 ± 4.65-0.8 ± 4.18
Total Protein, EW, n=2, 2, 0, 0-0.5 ± 3.540.0 ± 0.00NA ± NANA ± NA
SecondaryChange From Baseline in Direct Bilirubin, Indirect Bilirubin, Total Bilirubin, and Creatinine Values at Day 42/EW

Blood samples were collected for the measurement of direct bilirubin, indirect bilirubin, total bilirubin, and creatinine at Baseline and Day 42/EW. For all laboratory assessments, Baseline is the most recent recorded value at Screening or prior to Day -1/1. Change from Baseline was calculated as the Day 42/EW value minus the Baseline value.

Time frame:
Baseline and Day 42/EW
Reported as:
Mean · Micromoles per liter (µmol/L)
Change From Baseline in Direct Bilirubin, Indirect Bilirubin, Total Bilirubin, and Creatinine Values at Day 42/EW
Micromoles per liter (µmol/L)PlaceboFF/VI 100/25 µg PMFF/VI 200/25 µg PMPrednisolone 10 mg AM
Direct Bilirubin, Day 42, n=55, 51, 55, 12-0.6 ± 1.12-0.6 ± 1.02-0.5 ± 1.100.3 ± 0.75
Direct Bilirubin, EW, n=2, 2, 0, 0-1.0 ± 0.000.0 ± 0.00NA ± NANA ± NA
Indirect Bilirubin, Day 42, n=55, 51, 55, 12-2.0 ± 4.89-2.5 ± 3.20-1.4 ± 4.72-1.0 ± 2.76
Indirect Bilirubin, EW, n=2, 2, 0, 0-1.5 ± 2.12-2.0 ± 0.00NA ± NANA ± NA
Total Bilirubin, Day 42, n=55, 51, 55, 12-2.5 ± 5.66-3.2 ± 3.72-1.8 ± 5.67-0.8 ± 2.86
Total Bilirubin, EW, n=2, 2, 0, 0-2.5 ± 2.12-2.0 ± 0.00NA ± NANA ± NA
Creatinine, Day 42, n=55, 51, 55, 12-0.41 ± 8.6880.35 ± 8.0880.04 ± 8.0524.61 ± 9.585
Creatinine, EW, n=2, 2, 0, 00.00 ± 13.4350.95 ± 6.435NA ± NANA ± NA
SecondaryChange From Baseline in Chloride, Carbon Dioxide (CO2) Content/Bicarbonate, Glucose, Potassium, Sodium, and Urea/Blood Urea Nitrogen (BUN) Values at Day 42/EW

Blood samples were collected for the measurement of chloride, carbon dioxide (CO2) content/bicarbonate, glucose, potassium, sodium, and urea/blood urea nitrogen (BUN) at Baseline and Day 42/EW. For all laboratory assessments, Baseline is the most recent recorded value at Screening or prior to Day -1/1. Change from Baseline was calculated as the Day 42/EW value minus the Baseline value.

Time frame:
Baseline and Day 42/EW
Reported as:
Mean · Millimoles per liter (mmol/L)
Change From Baseline in Chloride, Carbon Dioxide (CO2) Content/Bicarbonate, Glucose, Potassium, Sodium, and Urea/Blood Urea Nitrogen (BUN) Values at Day 42/EW
Millimoles per liter (mmol/L)PlaceboFF/VI 100/25 µg PMFF/VI 200/25 µg PMPrednisolone 10 mg AM
Chloride, Day 42, n=55, 51, 55, 121.2 ± 2.540.9 ± 2.760.7 ± 3.06-1.0 ± 2.41
Chloride, EW, n=2, 2, 0, 02.0 ± 1.41-0.5 ± 0.71NA ± NANA ± NA
CO2 content/bicarbonate, Day 42, n=54, 50, 51, 12-1.0 ± 2.86-2.0 ± 2.98-1.5 ± 2.35-0.1 ± 3.12
CO2 content/bicarbonate, EW, n=2, 2, 0, 0-3.5 ± 2.120.0 ± 1.41NA ± NANA ± NA
Glucose, Day 42, n=55, 51, 55, 120.11 ± 1.1170.23 ± 1.037-0.03 ± 0.5730.40 ± 1.397
Glucose, EW, n=2, 2, 0, 01.00 ± 0.2830.40 ± 0.849NA ± NANA ± NA
Potassium, Day 42, n=54, 50, 51, 12-0.10 ± 0.385-0.11 ± 0.405-0.16 ± 0.3790.03 ± 0.599
Potassium, EW, n=2, 2, 0, 0-0.20 ± 0.283-0.65 ± 0.071NA ± NANA ± NA
Sodium, Day 42, n=55, 51, 55, 120.0 ± 2.03-0.1 ± 1.98-0.1 ± 3.01-0.2 ± 1.85
Sodium, EW, n=2, 2, 0, 01.5 ± 3.54-3.5 ± 0.71NA ± NANA ± NA
Urea/BUN, Day 42, n=55, 51, 55, 12-0.14 ± 1.4320.48 ± 1.441-0.00 ± 1.2360.94 ± 1.331
Urea/BUN, EW, n=2, 2, 0, 01.30 ± 0.283-0.85 ± 0.919NA ± NANA ± NA
SecondaryChange From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at Days 14, 28, 42, and Maximum Post-Baseline

SBP and DBP were measured at Baseline and at Days 14, 28, 42, and EW. Change from Baseline was calculated as the Day 42/EW value minus the Baseline value. Scheduled, unscheduled, and early withdrawal visits were used for the maximum post-Baseline assessment.

Time frame:
Days 14, 28, 42, and EW
Reported as:
Mean · Millimeters of mercury (mmHg)
Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at Days 14, 28, 42, and Maximum Post-Baseline
Millimeters of mercury (mmHg)PlaceboFF/VI 100/25 µg PMFF/VI 200/25 µg PMPrednisolone 10 mg AM
SBP, Day 14, n=58, 55, 56, 14-0.5 ± 11.68-1.9 ± 10.88-1.3 ± 10.53-1.0 ± 13.33
SBP, Day 28, n=57, 55, 56, 14-0.9 ± 9.55-0.7 ± 10.70-2.3 ± 11.66-3.9 ± 13.35
SBP, Day 42, n=55, 54, 56, 132.3 ± 11.96-0.4 ± 12.72-1.8 ± 11.201.5 ± 8.26
SBP, maximum post-Baseline, n=58, 56, 56, 156.2 ± 11.445.0 ± 10.883.9 ± 10.804.9 ± 8.61
DBP, Day 14, n=58, 55, 56, 140.0 ± 7.92-1.1 ± 8.26-0.6 ± 9.080.1 ± 8.55
DBP, Day 28, n=57, 55, 56, 141.8 ± 8.38-0.6 ± 7.630.1 ± 9.97-0.4 ± 8.11
DBP, Day 42, n=55, 54, 56, 131.2 ± 8.77-1.2 ± 9.130.3 ± 8.741.2 ± 8.69
DBP, maximum post-Baseline, n=58, 56, 56, 15-3.3 ± 7.04-5.2 ± 7.76-5.4 ± 9.00-4.9 ± 7.97
SecondaryChange From Baseline in Pulse Rate at Days 14, 28, 42, and Maximum Post-Baseline

Heart rate was measured at Baseline and at Days 14, 28, 42, and EW. Change from Baseline was calculated as the Day 42/EW value minus the Baseline value. Scheduled, unscheduled, and early withdrawal visits were used for the maximum post-Baseline assessment.

Time frame:
Days 14, 28, 42, and EW
Reported as:
Mean · Beats per minute
Change From Baseline in Pulse Rate at Days 14, 28, 42, and Maximum Post-Baseline
Beats per minutePlaceboFF/VI 100/25 µg PMFF/VI 200/25 µg PMPrednisolone 10 mg AM
Day 14, n=58, 55, 56, 141.5 ± 13.051.7 ± 10.700.0 ± 8.72-1.8 ± 7.92
Day 28, n=57, 55, 56, 142.9 ± 13.45-0.9 ± 9.32-1.9 ± 12.05-2.7 ± 11.89
Day 42, n=55, 54, 56, 13-0.1 ± 12.65-0.9 ± 11.430.9 ± 8.96-2.3 ± 9.10
Maximum post-Baseline, n=58, 56, 56, 158.0 ± 12.476.0 ± 9.865.5 ± 8.642.9 ± 9.13

Adverse events

Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—0/58 (0%)9/58 (15.5%)
FF/VI 100/25 µg PM—0/56 (0%)20/56 (35.7%)
FF/VI 200/25 µg PM—0/56 (0%)13/56 (23.2%)
Prednisolone 10 mg AM—0/15 (0%)5/15 (33.3%)
Most frequent other events
Showing 10 of 17
Most frequent other events
EventPlaceboFF/VI 100/25 µg PMFF/VI 200/25 µg PMPrednisolone 10 mg AM
HeadacheNervous system disorders5/5815/569/562/15
DizzinessNervous system disorders0/580/560/561/15
Facial palsyNervous system disorders0/580/560/561/15
Dyspnoea exertionalRespiratory, thoracic and mediastinal disorders0/580/560/561/15
Back painMusculoskeletal and connective tissue disorders0/581/562/561/15
NauseaGastrointestinal disorders1/580/560/561/15
HypotensionVascular disorders0/580/560/561/15
Varicose veinVascular disorders0/580/560/561/15
FatigueGeneral disorders0/580/560/561/15
InsomniaPsychiatric disorders0/580/560/561/15

Baseline characteristics

Age, Continuous
Age, Continuous(Years)PlaceboFF/VI 100/25 µg PMFF/VI 200/25 µg PMPrednisolone 10 mg AMTotal
Mean36.1 ± 15.4234.4 ± 15.6334.0 ± 13.7437.5 ± 14.1935.1 ± 14.82
Gender
Gender(Participants)PlaceboFF/VI 100/25 µg PMFF/VI 200/25 µg PMPrednisolone 10 mg AMTotal
Female273123687
Male312533998
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboFF/VI 100/25 µg PMFF/VI 200/25 µg PMPrednisolone 10 mg AMTotal
African American/African Heritage30104
American Indian or Alaska Native00101
Asian - Japanese Heritage00101
White - White/Caucasian/European Heritage55565315179
08

Study locations

17 sites
  • GSK Investigational Site
    Cypress, California 90630, United States
  • GSK Investigational Site
    Huntington Beach, California 92647, United States
  • GSK Investigational Site
    Oklahoma City, Oklahoma 73103, United States
  • GSK Investigational Site
    San Antonio, Texas 78229, United States
  • GSK Investigational Site
    Frankfurt, Hessen 60596, Germany
  • GSK Investigational Site
    Magdeburg, Sachsen-Anhalt 39112, Germany
  • GSK Investigational Site
    Grosshansdorf, Schleswig-Holstein 22927, Germany
  • GSK Investigational Site
    Berlin, 10117, Germany
  • GSK Investigational Site
    Berlin, 10787, Germany
  • GSK Investigational Site
    Hamburg, 20253, Germany
  • GSK Investigational Site
    Bialystok, 15-010, Poland
  • GSK Investigational Site
    Gdansk, 80-405, Poland
  • GSK Investigational Site
    Gidle, 97-540, Poland
  • GSK Investigational Site
    Krakow, 31-023, Poland
  • GSK Investigational Site
    Lodz, 93-513, Poland
  • GSK Investigational Site
    Olsztyn, 10-357, Poland
  • GSK Investigational Site
    Warszawa, 01-138, Poland
09

References and documents

Individual participant data

Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2010, a primary completion of Sep 2010 and a completion of Sep 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2013, 2 years 11 months after primary completion. A results delay was requested in Mar 2012.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 11, 2010
First posted
Mar 15, 2010
Start
Mar 2010
Primary completionActual
Sep 2010
CompletionActual
Sep 2010
Results delay requested
Mar 15, 2012
Results first posted
Aug 8, 2013
Last update
Jan 18, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 18, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01086410
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Mar 15, 2010
Start date
Mar 2010
Primary completion
Sep 2010
Completion
Sep 2010
Results posted
Aug 8, 2013
Last update
Jan 18, 2017

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Fluticasone furoate · Vilanterol · Prednisolone

Start the discussion